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Abstract
Rationale: The extent of protective effects of hemophilia against thrombotic events such as myocardial infarction (MI) and other
acute coronary syndromes remains to be determined, as major risk factors for cardiovascular disease exist despite factor VIII (FVIII)
deﬁciency. We present a case report of a 41-year-old male with severe hemophilia A and several cardiovascular risk factors.
Patient concerns: This morbidly obese patient developed chest pressure, followed by chest pain and difﬁculty in breathing
shortly after receiving on-demand treatment with intravenous recombinant FVIII (rFVIII) (turoctocog alfa) dosed per body weight.
Diagnoses: An electrocardiogram revealed a diagnosis of inferior ST-segment elevation MI.
Interventions: The patient underwent an urgent coronary angiography using a radial artery approach. During the next 12 months,
he received dual antiplatelet treatment, acetylsalicylic acid 100mg, and clopidogrel 75mg daily. His treatment for severe hemophilia A
was changed to plasma-derived FVIII replacement therapy.
Outcomes: During this 12-month period, he experienced several small bleeds in his elbows.
Conclusions: The temporal relationship between rFVIII infusion and onset of the MI suggests a possible association; however,
apart from obesity, the patient also had other major risk factors for arterial thrombosis, such as hypertension and smoking.
Furthermore, atherosclerotic disease and underlying atherosclerotic changes could not be excluded with certainty. This case
highlights the importance of studies assessing the impact of excess body weight on rFVIII dosing.
Abbreviations: FVIII = factor VIII, HDL = high-density lipoprotein, MI =myocardial infarction, RCA = right coronary artery, rFVIII =
recombinant FVIII.
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11. Introduction
Myocardial infarction (MI), or other acute coronary syndromes
in patients with hemophilia A, are not exceptional events.[1] Even
severe clotting factor VIII (FVIII) deﬁciency does not offer
protection against atherothrombotic complications,[2] although
MI may occur infrequently in these patients.[3,4] Conditions
predisposing to arterial occlusion, such as obesity, hypertension,
smoking, hypercholesterolemia, and diabetes mellitus, play a
dominant role in the pathogenesis of MI, with obesity being
endemic in the hemophilia community.[1,5] However, in several
reported cases, MI in patients with hemophilia occurred during
or immediately after the administration of antibleeding therapy,
without clear correlation to the state of the coronary arteries.[6]
Here, we discuss the case report of a patient with severe
hemophilia A and cardiovascular risk factors, who had an event
of acute MI that developed soon after administration of
recombinant FVIII (rFVIII).
2. Case study
A 41-year-old white male with severe hemophilia A (diagnosed
6 months after birth; baseline FVIII levels <1%) had been
treated with intravenous rFVIII (turoctocog alfa; NovoEight,
Novo Nordisk A/S, Bagsværd, Denmark) for just over 7 months
(informed consent was provided). Treatment was given as
intermittent, on-demand therapy performed in the home setting
to allow for early treatment of bleeding episodes that occurred
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history included morbid obesity (weight: 130kg; body mass
index: 41.03kg/m2), arterial hypertension, and smoking (20
cigarettes per day). He did not have a prior history of diabetes
mellitus or cardiovascular disease. As the patient had been
adopted, a family history of hemophilia A or cardiovascular
disease was not available.
On the evening before hospital admission, the patient experi-
enced pain in the left ankle and, suspecting bleeding in the joint, he
injected himself with 30IU/kg body weight turoctocog alfa. Ten
minutes after the injection, the patient developed chest pressure,
followed by chest pain and difﬁculty in breathing. He attempted to
alleviate the pain with tramadol. However, the pain continued to
get worse and, after midnight, he was admitted to the emergency
department.His blood pressurewas 150/120mmHgand his heart
rate was 100bpm. Acetylsalicylic acid and nitroglycerine were
immediately administered. He had severe arthropathy of both
knees, right hip, both elbows, and right ankle. Otherwise, his
physical examinationwas unremarkable except for tenderness and
slight restriction of movement in the left ankle.
An electrocardiogram showed ST-segment elevation in leads II,
III, and aVF, and a diagnosis of inferior ST-segment elevation MI
was established. The patient received 600mg of clopidogrel and
underwent an urgent coronary angiography using a radial artery
approach. This procedure revealed an acute thrombotic occlusion
of adominant right coronary artery (RCA)at the turnof themiddle
to distal segment. No signiﬁcant atherosclerotic changes in other
coronary arteries were detected and we proceeded with percuta-
neous coronary intervention of the RCA. A partial recanalization
of the thrombotic occlusion was achieved using a coronary wire
passage. However, due to the residual haziness at the site of the
lesion, we decided to complete the procedure with a single bare
metal stent (3.0/18mm) implantation. During the procedure, the
patient received 9000IU of unfractionated heparin, intracoronary.
Laboratory analysis showed an increase of troponin-T from
0.023mg/L initially to >10mg/L on the same day (normal upper
limit 0.014mg/L). Blood lipid test results were as follows: total
cholesterol 4.5mmol/L (normally <5.0mmol/L); triglycerides
2.83mmol/L (normally <1.7mmol/L); high-density lipoprotein
(HDL) 0.82mmol/L (normally >1.0mmol/L); and low-density
lipoprotein 2.34mmol/L (normally <3.0mmol/L). FVIII level of
activity on admission was 0.90k/IU/L. An investigation for
congenital prothrombotic conditions yielded no positive results
(no Factor V Leiden mutation and no mutations in prothrombin
or JAK2 genes). Chest X-ray showed an enlarged heart and
possible minor pleural effusion. Cardiac ultrasound indicated a
dilated left ventricle with an ejection fraction of 45% and mild
hypocontractility of the lateral wall, as well as inferior wall
akinesia with a small aneurism.
The rest of patient’s clinical course was unremarkable and he
was discharged from the hospital 6 days later. During the next
12 months, he received dual antiplatelet treatment, acetylsalicylic
acid 100mg, and clopidogrel 75mg daily. During this period, he
experienced several small bleeds in his elbows. The patient’s
treatment for severe hemophilia A was changed to plasma-
derived FVIII replacement therapy (1500–2000IU delivered
intravenously, twice weekly).3. Discussion
WhenMI is reported in patients with hemophilia A, it sometimes
occurs during or immediately after the infusion of concentrates
containing activated factors, such as plasma-derived activated2prothrombin complex concentrate or recombinant activated FVII
concentrates.[1] MI has also been reported in association with an
infusion of FVIII concentrates[7,8] and with desmopressin[9] in
patients with hemophilia, and described less frequently in severe
versus nonsevere hemophilia.[3,4] Nevertheless, the risk of same-
day thrombotic events following FVIII infusion appears to be
lower than other clotting factor products (odds ratio: 0.70; 95%
conﬁdence interval: 0.09–5.51) in patients with or without FVIII
deﬁciency.[6] Themost likely explanation for this association is an
acute elevation of clotting factors and/or the appearance of
activated clotting factors in the circulation contributing to an
ongoing process that concludes with the formation of a
pathologic thrombus. In the majority of these cases, the presence
of extensive atherosclerotic lesions, and multiple associated
thrombosis risk factors, makes the relative contribution of each
risk factor difﬁcult to ascertain.
In this case, the temporal relationship between the infusion of
coagulation factor and the onset of the MI suggests a certain
degree of causality. Nevertheless, several patient-related factors
may have contributed to the MI. The coronary artery was
occluded by fresh thrombus without apparent atherosclerotic
changes shortly after the administration of rFVIII. However,
elevated total cholesterol and low HDL suggest a risk of
atherosclerotic disease. The patient had several major risk factors
for arterial thrombosis, such as morbid obesity, hypertension,
and smoking.
Obese patients are at a high risk of cardiovascular diseases,
which can in part be explained by disturbances in the hemostatic
and ﬁbrinolytic systems. Adipocytes, growing in size and number,
are stimulated to secrete tissue factor, plasminogen activator
inhibitor, and other substances that may promote clot initiation
and formation.[10] Also, obesity is associatedwith increased levels
of ﬁbrinogen, Factor VII, von Willebrand factor in plasma,
disturbances in the protein C system, increased blood viscosity,
and erythrocyte hyperaggregability[10,11] All of these obesity-
related changes can occur in patients with hemophilia.[5]
Furthermore, to avoid overtreating obese individuals, rFVIII
dosing should be adapted individually, taking into account not
only body weight but also other anthropomorphic measures,
such as ideal body weight, as plasma volume is not proportional
to body weight.[12] In our case report, at admission (1hour after
the injection of rFVIII), the FVIII level of activity was 90%. In a
person with normal weight, assuming that every IU/kg of FVIII
injected raises the level by approximately 2%, the FVIII level
expected after administration of 30 IU/kg is 60%. Most likely, in
this case, the patient could have beneﬁted from a lower dose of
rFVIII, possibly reducing the risk of hypercoagulation super-
imposed over obesity-associated cardiovascular risk.
In conclusion, the temporal relationship between the onset of
acute MI and the use of replacement therapy with rFVIII suggests
an association in this individual. At the same time, it is possible
that these two events were coincidental, taking into consideration
the underlying high cardiovascular risk. This case illustrates the
importance of further studies assessing the impact of excess body
weight on rFVIII dosing and adequate changes in the guidelines
for the management of hemophilia in different subgroups.Acknowledgments
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